Turning points in obesity care: ADA 2025 showcases MariTide, Orforglipron, and CagriSema
Several high-stakes clinical trial readouts are set to define the next chapter of obesity management, as Novo Nordisk, Eli Lilly, and Amgen present critical data for their leading pipeline assets at ADA 2025. These updates will clarify which players strengthen their position in a market that has already been shaped by semaglutide (Novo) and tirzepatide (Lilly), establishing a multi-billion-dollar franchise.
Novo Nordisk will present full Phase 3 results for CagriSema, an injectable GLP-1/amylin co-agonist designed to deliver superior weight loss through dual mechanisms targeting satiety, gastric emptying, and energy regulation. The company previously suggested the asset could achieve ~25% weight loss, surpassing tirzepatide’s ~20.9% in SURMOUNT-1. However, topline data revealed only 20.4% reduction as limited patients were able to tolerate high doses raising questions about whether dose-limiting tolerability constrained efficacy. Full safety and discontinuation data at ADA will be critical in determining whether the asset underperformed due to modifiable factors (e.g., titration schemes) or inherent efficacy ceilings. Despite launching the first GLP-1 blockbuster, Novo has recently fallen behind Lilly in both market share and investor confidence. The trajectory of CagriSema could be pivotal in restoring momentum for Novo or widening the competitive gap.
Lilly is unveiling full Phase 3 ACHIEVE-1 results for orforglipron, its oral small molecule GLP-1, designed to deliver better bioavailability and efficacy compared to Novo’s peptide-based oral GLP-1 Rybelsus. Topline data showed 7.9% weight loss in a T2D population after 40 weeks, significantly above the 4% seen with Rybelsus at 26 weeks in PIONEER-1. Full results from ACHIEVE-1 at ADA will provide deeper insights into orforglipron’s tolerability, glycemic control, and weight loss efficacy, offering a clearer comparison to Rybelsus and informing potential market positioning.
Amgen will present Phase 2 results for MariTide, an injectable GLP-1 agonist/GIP antagonist designed to rival tirzepatide in efficacy while introducing a major advantage: monthly or bi-monthly dosing. Early data suggest MariTide delivers comparable weight loss to tirzepatide, which requires weekly injections. A monthly regimen with equal efficacy could reduce injection fatigue in patients, improve compliance, and create a commercial edge in a market increasingly focused on chronic, long-term weight management.
The obesity treatment landscape is entering a new era where tolerability and convenience will be as important as efficacy. ADA 2025 will not only determine which assets clear clinical hurdles, but also which players are best positioned to translate innovation into durable market leadership with their growing portfolios.
